Edition:
India

Swedish Orphan Biovitrum AB (publ) (SOBIV.ST)

SOBIV.ST on Stockholm Stock Exchange

117.25SEK
2:02pm IST
Change (% chg)

0.20kr (+0.17%)
Prev Close
117.05kr
Open
117.45kr
Day's High
117.75kr
Day's Low
116.75kr
Volume
40,346
Avg. Vol
588,986
52-wk High
143.80kr
52-wk Low
106.10kr

Chart for

About

Swedish Orphan Biovitrum publ AB is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers... (more)

Overall

Beta: 1.57
Market Cap(Mil.): kr34,172.46
Shares Outstanding(Mil.): 272.51
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.11 16.44
EPS (TTM): -- -- --
ROI: -- 14.85 10.61
ROE: -- 16.31 14.21

UPDATE 1-Sobi to scale up in North America as Q3 beats expectations

Oct 25 Rare-disease drug maker Swedish Orphan Biovitrum (Sobi) reported on Wednesday a bigger jump than expected in quarterly core profit, raised its profit and sales guidance, and said it planned to boost operations in North America.

25 Oct 2017

BRIEF-Swedish Orphan Biovitrum says Alprolix approved for use in Saudi Arabia‍​

* Alprolix approved for treatment of Hemofili B in Saudi Arabia.‍​ Source text for Eikon: Further company coverage: (Reporting By Johan Sennero)

25 Oct 2017

BRIEF-Sobi raises outlook as Q3 core profit beats expectations

* Swedish orphan biovitrum says ‍sobi now expects total revenues for full year to be in range of sek 6,300 to 6,400 m (6,100-6,200)​

25 Oct 2017

BRIEF-Sobi Q2 EBITA falls, raises 2017 guidance

* Swedish orphan biovitrum Q2 total revenue was SEK 1,639 mln (1,469)

19 Jul 2017

Earnings vs. Estimates